IDBiologics is dedicated to the discovery and development of human monoclonal antibodies (mAbs) aimed at preventing and treating infectious diseases. The company leverages a cutting-edge platform developed in the laboratory of Professor James Crowe at Vanderbilt University Medical Center. This innovative fully human mAb platform allows for the rapid discovery and optimization of therapeutic antibodies that exhibit broad and potent neutralizing activity against various viral targets. This technology positions IDBiologics at the forefront of mAb research, enabling the creation of effective treatments for a wide range of infectious diseases.

The company's pipeline is notable for its diversity, featuring six clinical lead candidate molecules targeting different infectious agents, each supported by robust proof of concept in animal studies. This extensive pipeline underscores IDBiologics' commitment to addressing significant health threats through advanced antibody therapies. Their recent collaboration with the Department of Defense further highlights their strategic focus on developing antibody medicines to combat infectious disease threats, reinforcing their role as a key player in the field of infectious disease therapeutics.

United States

IDBiologics is a biotech startup that is focused on developing monoclonal antibodies against infectious disease targets with high unmet medical need. The company is located in Nashville, TN and also has an office in San Mateo, CA.

IDBiologics

Company Details